GoodRx Holdings, Inc.GDRX stock score: 58/100
$3.02 · -10.12% · Scored Nov 19, 2026
- Technical
- 36
- Fundamental
- 63
- News
- —
The reading
GoodRx (GDRX) scores 58 out of 100, which reads neutral, higher than 69% of Healthcare stocks and 69% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 63, technicals 36.
Among the fundamentals, Earnings Growth (Annual) at 99 and Free Cash Flow Yield at 97 score highest, while Earnings Growth (Quarterly) at 1 weighs the most against it.
On the daily chart, trend-following indicators average 27 and contrarian oscillators 68 — a split worth reading before trusting the technical total.
Since Aug 23, 2026 the composite has ranged from 48 to 62, and it is up 6 points over the period.
About GoodRx
GoodRx (GDRX) operates a consumer platform that helps people in the United States compare prescription drug prices and save money at pharmacies. Through its website and app, consumers find discounted prices and free coupon codes that they present at retail pharmacies when filling a prescription. GoodRx earns most of its revenue from fees paid by pharmacy benefit managers when its codes are used, which it reports as prescription transactions revenue. It also sells subscription plans that offer lower prices on many medications, including programs aimed at weight loss drugs. Its Pharma Direct business, formerly called pharma manufacturer solutions, sells advertising and consumer-direct pricing programs to drug manufacturers that want to reach patients and help them afford branded medicines.
GoodRx competes with other discount card providers such as SingleCare and Optum Perks, with Mark Cuban Cost Plus Drug Company and Amazon Pharmacy, and with direct-to-consumer drug programs run by manufacturers. Its edge rests on a widely recognized consumer brand, broad acceptance at pharmacies and pricing data across many drugs and locations. Investors who follow GDRX stock tend to watch monthly active consumers and prescription transactions revenue. Growth in Pharma Direct and subscription revenue is closely followed. Pharmacy closures, contract terms with pharmacy benefit managers, changes in drug pricing policy, margins, debt and share buybacks are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward GDRX’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
63Pulling it up
Net income growth from the prior fiscal year to the latest.
Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.
Forward P/E ratio uses estimated future earnings to calculate valuation.
Holding it back
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
Trailing P/E ratio uses the last 12 months of actual earnings.
Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.
36 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical · daily
33Pulling it up
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Commodity Channel Index (14) measures how far price has moved from its average.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Simple Moving Average (10-period) smooths price action over 10 periods.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 27 | 1 |
| Daily | 33 | 3 |
| Weekly | 37 | 2 |
| Monthly | 44 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 20, 2026 | 58 |
| Nov 19, 2026 | 59 |
| Nov 18, 2026 | 60 |
| Nov 15, 2026 | 61 |
| Nov 14, 2026 | 61 |
| Nov 13, 2026 | 62 |
| Nov 12, 2026 | 56 |
| Nov 11, 2026 | 53 |
| Nov 7, 2026 | 52 |
| Nov 6, 2026 | 52 |
| Nov 5, 2026 | 56 |
| Nov 4, 2026 | 52 |
| Nov 2, 2026 | 53 |
| Nov 1, 2026 | 52 |
| Oct 30, 2026 | 53 |
| Oct 29, 2026 | 52 |
| Oct 27, 2026 | 53 |
| Oct 26, 2026 | 54 |
| Oct 25, 2026 | 55 |
| Oct 24, 2026 | 55 |
| Oct 23, 2026 | 54 |
| Oct 22, 2026 | 55 |
| Oct 21, 2026 | 53 |
| Oct 19, 2026 | 51 |
| Oct 18, 2026 | 50 |
| Oct 17, 2026 | 50 |
| Oct 16, 2026 | 53 |
| Oct 15, 2026 | 52 |
| Oct 14, 2026 | 52 |
| Oct 13, 2026 | 53 |
| Oct 11, 2026 | 53 |
| Oct 10, 2026 | 53 |
| Oct 9, 2026 | 53 |
| Oct 8, 2026 | 48 |
| Oct 7, 2026 | 49 |
| Oct 5, 2026 | 51 |
| Oct 4, 2026 | 50 |
| Oct 3, 2026 | 50 |
| Oct 2, 2026 | 50 |
| Oct 1, 2026 | 49 |
| Sep 30, 2026 | 49 |
| Sep 29, 2026 | 48 |
| Sep 28, 2026 | 49 |
| Sep 27, 2026 | 50 |
| Sep 26, 2026 | 50 |
| Sep 25, 2026 | 50 |
| Sep 24, 2026 | 52 |
| Sep 23, 2026 | 52 |
| Sep 22, 2026 | 52 |
| Sep 21, 2026 | 51 |
| Sep 20, 2026 | 52 |
| Sep 19, 2026 | 52 |
| Sep 18, 2026 | 52 |
| Sep 17, 2026 | 51 |
| Sep 16, 2026 | 50 |
| Sep 15, 2026 | 52 |
| Sep 14, 2026 | 53 |
| Sep 13, 2026 | 51 |
| Sep 12, 2026 | 51 |
| Sep 11, 2026 | 51 |
| Sep 10, 2026 | 50 |
| Sep 9, 2026 | 50 |
| Sep 8, 2026 | 53 |
| Sep 6, 2026 | 53 |
| Sep 5, 2026 | 52 |
| Sep 4, 2026 | 53 |
| Sep 2, 2026 | 53 |
| Sep 1, 2026 | 53 |
| Aug 31, 2026 | 51 |
| Aug 29, 2026 | 52 |
| Aug 28, 2026 | 52 |
| Aug 27, 2026 | 52 |
| Aug 25, 2026 | 50 |
| Aug 23, 2026 | 52 |
Key facts
- Market cap
- $1.0B
- Sector
- Healthcare
- Industry
- Health Information Services
- Beta
- 1.66
- Risk grade (1–10)
- —
- Next earnings
- Nov 23, 2026
Health Information Services peers
| Company | Market cap | Score |
|---|---|---|
| HTFL Heartflow | $3.9B | 52 |
| PRVA Privia Health Group | $3.2B | 64 |
| SDGR Schrödinger | $2.0B | 50 |
| CERT Certara | $1.6B | 55 |
| OMCL Omnicell | $1.5B | 53 |
| TDOC Teladoc Health | $1.4B | 54 |
All Health Information Services stocks, highest-scored first
Questions
What is GDRX's stock rating today?
GDRX scores 58/100 (Neutral) as of Nov 19, 2026: technical 36, fundamental 63. Scores are recomputed every night.
What does GoodRx do?
GoodRx (GDRX) operates a consumer platform that helps people in the United States compare prescription drug prices and save money at pharmacies. Through its website and app, consumers find discounted prices and free coupon codes that they present at retail pharmacies when filling a prescription.
Is GDRX stock a buy?
The score is not a buy or sell recommendation. A 58 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the GDRX score calculated?
98 weighted scorers feed it today: 36 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/gdrx/"><img src="https://stocksscores.com/stocks/gdrx/badge.svg" alt="GDRX stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/gdrx/)